Abstract: This study aimed to investigate the effects of conjugated linoleic acid glyceride oil (CLA-TG) and microencapsulated CLA-TG emulsion on high-fat diet induced non-alcoholic fatty liver disease in rats.Male Sprague-Dawley rats were fed with high-fat diet for 6 weeks to establish the non-alcoholic fatty liver disease model.At the same time, the intervention groups were fed with CLA-TG oil and microencapsulated CLA-TG emulsion. Body weight and food intake were recorded.After 6 weeks treatment, the liver and blood were collected to exam the liver function indicators alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) in serum and triglycerides (TG) in liver. And oil-red O staining was used to observe the lipid accumulation of liver tissue. Results showed that the food intake of all groups showed no significant difference. Compared with the control group, the body weight in the model group increased significantly (P<0.01). The levels of serum ALT、AST、TC、TG、LDL-C were also significantly elevated (P<0.01) and HDL-C were significantly decreased (P<0.05). Sever steatosis were observed in the liver tissue which showed excessive TG and lipid accumulation (P<0.01).Compared with the model group, body weight, serum blood lipids levels, liver TG and lipid accumulation were significantly lower in CLA-TG group and microencapsulated CLA-TG emulsion groups (P<0.05). Moreover, the microencapsulated CLA-TG emulsion group showed better amelioration effects. The ingestion of CLA-TG can improve non-alcoholic fatty liver disease in rats and microencapsulated CLA-TG emulsion can further enhance the protective effects.
 PARRY S A,HODSON L.Influence of dietary macronutrients on liver fat accumulation and metabolism[J].Journal of Investigative Medicine,2017,65(8):1 102-1 115.  ANGULO P.Nonalcoholic fatty liver disease//Encyclopedia of Gastroenterology[M].Amsterdam:Elsevier,2004:733-736.  TILG H,MOSCHEN A R,RODEN M.NAFLD and diabetes mellitus[J].Nature Reviews Gastroenterology & Hepatology,2017,14(1):32-42.  KOBA K,YANAGITA T.Health benefits of conjugated linoleic acid (CLA)[J].Obesity Research & Clinical Practice,2014,8(6):e525-e532.  GAJDZIOK J,VRANÍKOVÁ B.Enhancing of drug bioavailability using liquisolid system formulation[J].Ceska a Slovenska Farmacie,2015,64(3):55-66.  SUN R M,KANG X H,ZHAO Y,et al.Sirtuin 3-mediated deacetylation of acyl-CoA synthetase family member 3 by protocatechuic acid attenuates non-alcoholic fatty liver disease[J].British Journal of Pharmacology,2020,177(18):4 166-4 180.  SHAN W,GAO L,ZENG W,et al.Activation of the SIRT1/p66 shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease[J].Cell Death & Disease,2015,6(7):e1833.  WEN J,XU B,SUN Y C,et al.Paeoniflorin protects against intestinal ischemia/reperfusion by activating LKB1/AMPK and promoting autophagy[J].Pharmacological Research,2019,146:104308.  SHI X,SUN R M,ZHAO Y,et al.Promotion of autophagosome-lysosome fusion via salvianolic acid A-mediated SIRT1 up-regulation ameliorates alcoholic liver disease[J].RSC Advances,2018,8(36):20 411-20 422.  RIVA G,VILLANOVA M,CIMA L,et al.Oil red O is a useful tool to assess donor liver steatosis on frozen sections during transplantation[J].Transplantation Proceedings,2018,50(10):3 539-3 543.  钟晓怡, 林云,郭艳,等.高脂小鼠脂肪肝组织油红O特殊染色的应用[J].上海预防医学,2018,30(10):873-877. ZHONG X Y,LIN Y,GUO Y,et al.Oil-red O special staining techniques applied in fatty liver tissue of hyperlipidemic mouse[J].Shanghai Journal of Preventive Medicine,2018,30(10):873-877.  POLYZOS S A,KOUNTOURAS J,MANTZOROS C S.Obesity and nonalcoholic fatty liver disease:From pathophysiology to therapeutics[J].Metabolism,2019,92:82-97.  张配配, 李景贤,李蒙丽,等.番茄红素对非酒精性脂肪肝大鼠糖脂代谢及炎症水平的影响[J].卫生研究,2020,49(2):254-258;271. ZHANG P P,LI J X,LI M L,et al.Effects of lycopene on metabolism of glycolipid and inflammation in non-alcoholic fatty liver disease rats[J].Journal of Hygiene Research,2020,49(2):254-258;271.  MATO J M,ALONSO C,NOUREDDIN M,et al.Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2019,25(24):3 009-3 020.  PERUMPAIL B J,KHAN M A,YOO E R,et al.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J].World Journal of Gastroenterology,2017,23(47):8 263-8 276.  CHEN S C,LIN Y H,HUANG H P,et al.Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population[J].Nutrition,2012,28(5):559-565.  YANG J M,SUN Y,WANG M,et al.Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2019,25(34):5 105-5 119.  LEHNEN T E,DA SILVA M R,CAMACHO A,et al.A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism[J].Journal of the International Society of Sports Nutrition,2015,12:36.  MASLAK E,BUCZEK E,SZUMNY A,et al.Individual CLA isomers,c9t11 and t10c12,prevent excess liver glycogen storage and inhibit lipogenic genes expression induced by high-fructose diet in rats[J].Biomed Research International,2015,2015:535 982.  祝彤彤, 张辉珍,王晓滨,等.共轭亚油酸甘油酯对大鼠血清脂肪酸组成影响的研究[J].现代生物医学进展,2016,16(15):2 842-2 846. ZHU T T,ZHANG H Z,WANG X B,et al.Effects of conjugated linoleic acid glycerides on the composition of serum fatty acid in rats[J].Progress in Modern Biomedicine,2016,16(15):2 842-2 846.  NEUBAUER M P,POEHLMANN M,FERY A.Microcapsule mechanics:From stability to function[J].Advances in Colloid and Interface Science,2014,207:65-80.  LÓPEZ-LLUCH G,DEL POZO-CRUZ J,SÁNCHEZ-CUESTA A,et al.Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization[J].Nutrition,2019,57:133-140.  刘明, 徐维锋,张显仁,等.共轭亚油酸甘油酯的储存稳定性研究[J].中国油脂,2012,37(10):50-52. LIU M,XU W F,ZHANG X R,et al.Storage stability of conjugated linoleic acid glyceride[J].China Oils and Fats,2012,37(10):50-52.  YOUNOSSI Z,ANSTEE Q M,MARIETTI M,et al.Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J].Nature Reviews Gastroenterology & Hepatology,2018,15(1):11-20.  POLYZOS S A,KOUNTOURAS J,MANTZOROS C S.Adipose tissue,obesity and non-alcoholic fatty liver disease[J].Minerva Endocrinologica,2017,42(2):92-108.  ALEXANDER M,LOOMIS A K,VAN DER LEI J,et al.Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD:Real-world study of 18 million patients in four European cohorts[J].BMC Medicine,2019,17(1):95.  MA M J,DUAN R,ZHONG H,et al.The crosstalk between fat homeostasis and liver regional immunity in NAFLD[J].Journal of Immunology Research,2019,2019:3954890.  BYRNE C D,TARGHER G.NAFLD:A multisystem disease[J].Journal of Hepatology,2015,62(1):S47-S64.  RINELLA M E,SANYAL A J.Management of NAFLD:A stage-based approach[J].Nature Reviews Gastroenterology & Hepatology,2016,13(4):196-205.  RINELLA M E,SANYAL A J.Management of NAFLD:A stage-based approach[J].Nature Reviews.Gastroenterology & Hepatology,2016,13(4):196-205.